Order Article Reprints

Yendewa GA, Griffiss JM, Gray WA, Healen A, Proskin HM, Fulton SA, O’Riordan MA, Hoppel C, Blumer JL, Salata RA. Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers. Antibiotics. 2022; 11(4):490. https://doi.org/10.3390/antibiotics11040490

Yendewa, George A., John McLeod Griffiss, Wesley A. Gray, Amanda Healen, Howard M. Proskin, Scott A. Fulton, Mary Ann O’Riordan, Charles Hoppel, Jeffrey L. Blumer, and Robert A. Salata. 2022. "Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers" Antibiotics 11, no. 4: 490. https://doi.org/10.3390/antibiotics11040490

Yendewa, G. A., Griffiss, J. M., Gray, W. A., Healen, A., Proskin, H. M., Fulton, S. A., O’Riordan, M. A., Hoppel, C., Blumer, J. L., & Salata, R. A. (2022). Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers. Antibiotics, 11(4), 490. https://doi.org/10.3390/antibiotics11040490